Strain	Genotype and RNAi treatment	Trial	Mean lifespan ± SEM (days)	% Difference	N (total)	*p*
GA303	*rrf-3; daf-2* control RNAi	1	29.2 ± 0.98		73 (98)	-
GA303	*rrf-3; daf-2 aakg-4* RNAi	1	28.0 ± 0.72	-3.8 [b]	78 (96)	0.047 [a]
GA303	*rrf-3; daf-2 aakg-5* RNAi	1	27.5 ± 1.08	-5.6 [b]	56 (82)	NS [a]
NL2099	*rrf-3* control RNAi	2	14.8 ± 0.52		86 (99)	
GA303	*rrf-3; daf-2* control RNAi	2	28.4 ± 1.08		86 (88)	<0.0001 [b]
GA303	*rrf-3; daf-2 aakg-4* RNAi	2	23.2 ± 0.79	-18.4 [b]	109 (109)	<0.0001 [a]
GA303	*rrf-3; daf-2 aakg-5* RNAi	2	25.9 ± 0.99	-9.0 [b]	108 (108)	0.07 [a]
NL2099	*rrf-3* control RNAi	3	13.7 ± 0.47		82 (82)	-
GA303	*rrf-3; daf-2* control RNAi	3	26.5 ± 0.83		106 (118)	<0.0001 [b]
GA303	*rrf-3; daf-2 aakg-4* RNAi	3	22.9 ± 0.70	-13.7 [b]	108 (108)	<0.0001 [a]
GA303	*rrf-3; daf-2 aakg-5* RNAi	3	26.0 ± 1.10	-2.1 [b]	81 (81)	NS [a]
NL2099	*rrf-3* control RNAi	4	12.6 ± 0.34		119 (123)	-
NL2099	*rrf-3 aakg-4* RNAi	4	11.8 ± 0.35	-6.5 [a]	79 (81)	0.08 [b]
GA303	*rrf-3; daf-2* control RNAi	4	26.6 ± 0.86		127 (127)	<0.0001 [b]
GA303	*rrf-3; daf-2 aakg-4* RNAi	4	20.0 ± 0.72	-24.8 [b]	102 (102)	<0.0001 [a/b]
GA303	*rrf-3; daf-2 aakg-5* RNAi	4	17.8 ± 0.72	-32.9 [b]	114 (114)	<0.0001 [a/b]
NL2099	*rrf-3* control RNAi	5	11.6 ± 0.39		49 (50)	-
NL2099	*rrf-3 aakg-4* RNAi	5	10.8 ± 0.36	-6.9 [a]	49 (50)	NS [b]
NL2099	*rrf-3 aakg-5* RNAi	5	10.9 ± 0.39	-5.9 [a]	50 (50)	NS [b]
GA303	*rrf-3; daf-2* control RNAi	5	27.9 ± 1.01		43 (50)	<0.0001 [b]
GA303	*rrf-3; daf-2 aakg-4* RNAi	5	22.9 ± 0.53	-18.0 [b]	47 (50)	<0.0001 [a/b]
GA303	*rrf-3; daf-2 aakg-5* RNAi	5	29.0 ± 0.72	+4.0 [b]	47 (50)	NS [a] <0.0001 [b]
NL2099	*rrf-3* control RNAi	6	9.2 ± 0.27		75(75)	-
NL2099	*rrf-3 aakg-4* RNAi	6	10.3 ± 0.26	+11.8 [a]	73 (75)	0.005 [a]
GA303	*rrf-3; daf-2* control RNAi	6	27.1 ± 0.47		56 (60)	<0.0001 [a]
GA303	*rrf-3; daf-2 aakg-4* RNAi	6	24.1 ± 0.52	-10.8 [b]	73 (75)	<0.0001 [a] 0.0002 [b]
NL2099	*rrf-3* control RNAi	7	12.1 ± 0.33		67 (67)	-
NL2099	*rrf-3 aakg-4* RNAi	7	11.0 ± 0.31	-8.9 [a]	66 (68)	0.02 [b]
NL2099	*rrf-3 aakg-5* RNAi	7	12.0 ± 0.40	-0.8 [a]	65 (67)	NS [b]
	N2 control RNAi	8	9.7 ± 0.25		96 (99)	
	N2 *aakg-4* RNAi	8	10.2 ± 0.22	+5.22 [a]	116 (122)	0.1370 [a]
	N2 *aakg-5* RNAi	8	10.7 ± 0.27	+10.61 [a]	98 (99)	0.0045 [a]
GA1071	*aakg-4* control RNAi	8	10.8 ± 0.26		96 (99)	0.0027 [a]
GA1071	*aakg-4; aakg-5* RNAi	8	12.2 ± 0.21	+12.37 [c]	97 (97)	0.0005 [c]
DR1567	*daf-2* control RNAi	8	21.5 ± 0.79		80 (85)	<0.0001 [a]
DR1567	*daf-2 aakg-4* RNAi	8	19.7 ± 0.69	-8.43 [b]	106 (111)	0.0013 [b]

DR1567	*daf-2 aakg-5* RNAi	8	16.9 ± 0.69	-21.24[b]	55 (67)	<0.0001[b]
	N2 control RNAi	9	9.9 ± 0.29		100 (100)	
	N2 *aakg-4* RNAi	9	9.9 ± 0.34	+0.68 [a]	64 (64)	NS [a]
	N2 *aakg-5* RNAi	9	10.0 ± 0.31	+1.72 [a]	100 (100)	NS [a]
GA1071	*aakg-4* control RNAi	9	10.4 ± 0.26		98 (99)	NS [a]
GA1071	*aakg-4; aakg-5* RNAi	9	10.6 ± 0.29	+2.46 [c]	100 (100)	NS [c]
DR1567	*daf-2* control RNAi	9	23.8 ± 0.71		85 (87)	<0.0001[a]
DR1567	*daf-2 aakg-4* RNAi	9	20.0 ± 0.57	-15.72 [b]	95 (95)	<0.0001[b]
DR1567	*daf-2 aakg-5* RNAi	9	20.2 ± 0.74	-14.92 [b]	90 (90)	0.0028 [b]
GA1072	*daf-2;aakg-4* control RNAi	9	18.2 ± 1.00		38 (38)	<0.0001[b]
GA1072	*daf-2;aakg-4 aakg-5* RNAi	9	19.7 ± 0.74	+7.95 [d]	80 (80)	NS [d]
DR1567	*daf-2* control RNAi	10	24.1 ± 0.73		105 (115)	-
DR1567	*daf-2 aakg-5* RNAi	10	18.5 ± 0.75	-23.40 [b]	99 (101)	<0.0001[b]
GA1072	*daf-2;aakg-4* control RNAi	10	18.9 ± 0.73	-21.65 [b]	71 (71)	<0.0001[b]
GA1072	*daf-2;aakg-4 aakg-5* RNAi	10	19.5 ± 0.67	+3.23 [d]	86 (95)	NS [d]

Table S8. *aakg-4* and *aakg-5* RNAi shorten *daf-2* lifespan.